NCT05624190View on ClinicalTrials.gov

Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization

PHASE4RecruitingINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

February 16, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Ischemic Stroke, Acute
Interventions
DRUG

Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)

The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.

OTHER

Best Medical Management

Best Medical Management

Trial Locations (1)

100070

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER